Volume 17, Number 3—March 2011
Dispatch
Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China
Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin Ma
Table 2
Second-line drug resistance of 107 MDR Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*
| Drugs | No. isolates | Rate, % |
|---|---|---|
| Overall second-line drug resistance | 65 | 60.7 |
| FQ | 57 | 53.3 |
| AMK | 19 | 17.8 |
| CPM | 24 | 22.4 |
| PAS |
18 |
16.8 |
| XDR, total | 20 | 18.7 |
| FQ + AMK | 4 | 3.7 |
| FQ + CPM | 4 | 3.7 |
| FQ + AMK + CPM | 5 | 4.7 |
| FQ + AMK + PAS | 2 | 1.9 |
| FQ + CPM + PAS | 3 | 2.8 |
| FQ + AMK + CPM + PAS | 2 | 1.9 |
*MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid; XDR, extensively drug-resistant.
